Education
About Us
Working with TipRanks
Follow Us
Eterna Therapeutics (ERNA)
NASDAQ:ERNA
ERNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.09 - $18.75
Previous Close$0.34
Volume440.10K
Average Volume (3M)140.61K
Market Cap
$8.74M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.25
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.21
Shares Outstanding7,670,889
10 Day Avg. Volume261,538
30 Day Avg. Volume140,612
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Eterna Therapeutics News
ERNA FAQ
What was Eterna Therapeutics’s price range in the past 12 months?
Eterna Therapeutics lowest stock price was $1.09 and its highest was $18.75 in the past 12 months.
What is Eterna Therapeutics’s market cap?
Eterna Therapeutics’s market cap is $8.74M.
When is Eterna Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Eterna Therapeutics’s earnings last quarter?
Eterna Therapeutics released its earnings results on Nov 08, 2022. The company reported -$2.488 earnings per share for the quarter, missing the consensus estimate of -$2.2 by -$0.288.
Is Eterna Therapeutics overvalued?
According to Wall Street analysts Eterna Therapeutics’s price is currently Overvalued.
Does Eterna Therapeutics pay dividends?
Eterna Therapeutics does not currently pay dividends.
What is Eterna Therapeutics’s EPS estimate?
Eterna Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eterna Therapeutics have?
Eterna Therapeutics has 7,670,889 shares outstanding.
What happened to Eterna Therapeutics’s price movement after its last earnings report?
Eterna Therapeutics reported an EPS of -$2.488 in its last earnings report, missing expectations of -$2.2. Following the earnings report the stock price went up 3.67%.
Which hedge fund is a major shareholder of Eterna Therapeutics?
Currently, no hedge funds are holding shares in ERNA
Eterna Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-94.01%
12-Months-Change
Fundamentals
Return on Equity
-2264.31%
Trailing 12-Months
Asset Growth
-83.69%
Trailing 12-Months
Company Description
Eterna Therapeutics
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Technical Analysis
Plus Therapeutics
―
Minerva Neurosciences
―
Affimed
―
GeoVax Labs
―
Addex Therapeutics
―
Ownership Overview
32.72% Insiders
0.45% Mutual Funds
0.76% Other Institutional Investors
66.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---